LDR Holding Corp CFO Unloads $543,800 in Stock (LDRH)
LDR Holding Corp (NASDAQ:LDRH) CFO Robert Mcnamara unloaded 20,000 shares of the stock on the open market in a transaction dated Friday, August 15th. The shares were sold at an average price of $27.19, for a total value of $543,800.00. Following the sale, the chief financial officer now directly owns 346 shares of the company’s stock, valued at approximately $9,408. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of LDR Holding Corp (NASDAQ:LDRH) traded up 4.24% on Friday, hitting $27.07. 472,620 shares of the company’s stock traded hands. LDR Holding Corp has a 52 week low of $17.79 and a 52 week high of $40.39. The stock’s 50-day moving average is $23.63 and its 200-day moving average is $26.66. The company’s market cap is $702.9 million.
LDR Holding Corp (NASDAQ:LDRH) last announced its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.05. The company had revenue of $34.80 million for the quarter, compared to the consensus estimate of $31.14 million. LDR Holding Corp’s revenue was up 30.8% compared to the same quarter last year. Analysts expect that LDR Holding Corp will post $-0.62 EPS for the current fiscal year.
LDRH has been the subject of a number of recent research reports. Analysts at Piper Jaffray raised their price target on shares of LDR Holding Corp from $38.00 to $40.00 in a research note on Thursday, August 7th. They now have an “overweight” rating on the stock. Analysts at RBC Capital initiated coverage on shares of LDR Holding Corp in a research note on Monday, June 23rd. They set an “outperform” rating and a $34.00 price target on the stock. Five analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $35.50.
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and surgical technologies for the treatment of patients suffering from spine disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.